Breakingviews: Alexion's pricey play

The rare-disease drugmaker's $8.4 billion bid for rival Synageva includes a 136 percent premium, but Robert Cyran and Reynolds Holding explain why that could make sense.

from Reuters Video: Breakingviews http://ift.tt/1c6emsM
via IFTTT